Literature DB >> 15902296

Protein expression analysis of chromosome 12 candidate genes in chronic lymphocytic leukemia (CLL).

D Winkler1, C Schneider, A Kröber, L Pasqualucci, P Lichter, H Döhner, S Stilgenbauer.   

Abstract

The pathogenic role of trisomy 12 in chronic lymphocytic leukemia (CLL) remains unresolved, but recently an upregulated RNA expression level has been observed for chromosome 12 candidate genes. In the current study, the protein expression of chromosome 12 candidate genes was characterized by comparing CLL cases with (n=58) or without (n=16) trisomy 12, CD19+-B-cells and cell lines (JVM-2, EHEB, JURKAT). Immunoblotting was performed to quantify the levels of AID, APAF-1, ARF3, CCND2, CDK2, CKD4, GLI, MDM-2, p27, Smac/DIABLO and STAT6 (signal transducer and activator of transcription 6). The cell lines showed distinct expression patterns for CCND2, MDM-2, p27, Smac/DIABLO and STAT6, and displayed higher levels of CDK2 and CDK4 than the CLL cases. JURKAT and the CLL cases expressed uniformly high levels of p27, but low levels of CCND2. AID expression in the CLL cases was weak with slight variations regardless of the subgroup affiliation. The expression of the investigated proteins was independent of the trisomy 12 status as well as of the VH mutation status. The comparison of CD19+-B-cells with CLL revealed higher protein levels in CLL for CDK4, p27, Smac/DIABLO and STAT6. Further studies including protein expression experiments in genetic high-risk subgroups of CLL have to elucidate whether these proteins qualify as candidates for targeted CLL therapies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15902296     DOI: 10.1038/sj.leu.2403778

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

1.  Frequent DAP kinase but not p14 or Apaf-1 hypermethylation in B-cell chronic lymphocytic leukemia.

Authors:  C S Chim; T K Fung; K F Wong; J S Lau; R Liang
Journal:  J Hum Genet       Date:  2006-08-03       Impact factor: 3.172

2.  Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia.

Authors:  Dirk Kienle; Axel Benner; Carolin Läufle; Dirk Winkler; Christof Schneider; Andreas Bühler; Thorsten Zenz; Annett Habermann; Ulrich Jäger; Peter Lichter; Riccardo Dalla-Favera; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

3.  Genome-wide assessment of recurrent genomic imbalances in canine leukemia identifies evolutionarily conserved regions for subtype differentiation.

Authors:  Sarah C Roode; Daniel Rotroff; Anne C Avery; Steven E Suter; Dorothee Bienzle; Joshua D Schiffman; Alison Motsinger-Reif; Matthew Breen
Journal:  Chromosome Res       Date:  2015-06-03       Impact factor: 5.239

Review 4.  Pharmacological activation of wild-type p53 in the therapy of leukemia.

Authors:  Kensuke Kojima; Jo Ishizawa; Michael Andreeff
Journal:  Exp Hematol       Date:  2016-06-18       Impact factor: 3.084

5.  Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice.

Authors:  Pieter Van Vlierberghe; Steven Goossens; Tim Pieters; Sara T'Sas; Stijn Vanhee; André Almeida; Yasmine Driege; Juliette Roels; Wouter Van Loocke; Willem Daneels; Mathijs Baens; Arnaud Marchand; Maaike Van Trimpont; Filip Matthijssens; Julie Morscio; Kelly Lemeire; Béatrice Lintermans; Lindy Reunes; Patrick Chaltin; Fritz Offner; Jo Van Dorpe; Tino Hochepied; Geert Berx; Rudi Beyaert; Jens Staal
Journal:  J Exp Med       Date:  2021-08-18       Impact factor: 14.307

6.  Investigation of MDM2 Oncogene Copy Number Alterations in Cases of Chronic Lymphocytic Leukemia

Authors:  Şule Darbaş; Çiğdem Aydın; Ozan Salim; Sibel Berker Karaüzüm
Journal:  Turk J Haematol       Date:  2018-10-16       Impact factor: 1.831

Review 7.  Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go.

Authors:  Anna Puiggros; Gonzalo Blanco; Blanca Espinet
Journal:  Biomed Res Int       Date:  2014-05-22       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.